乳腺癌患者中基于阿霉素化疗继发的微粒与心脏毒性
Microparticles and cardiotoxicity secondary to doxorubicin-based chemotherapy in breast cancer patients.
作者信息
Pestana Rodrigo M C, Teixeira-Carvalho Andréa, Dos Santos Luara I, de Oliveira Angélica N, Soares Cintia E, Sabino Adriano de P, Simões Ricardo, Gomes Karina B
机构信息
Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Departamento de Ciências Fisiológicas, Universidade Federal do Maranhão, São Luís, Maranhão, Brazil.
Fundação Oswaldo Cruz (Fiocruz), Instituto René Rachou, Belo Horizonte, MG, Brazil.
出版信息
Int J Cardiol. 2024 Jan 15;395:131435. doi: 10.1016/j.ijcard.2023.131435. Epub 2023 Oct 16.
Doxorubicin (DOXO)-cardiotoxicity is a limiting factor for breast cancer chemotherapy. The relationship between microparticles (MPs) and cardiotoxicity remains unclear. MPs can be released under varying pathophysiological conditions. Thereby, this study aimed to assess MPs derived from cardiomyocytes (CardioMPs), platelets (PMPs) and those that expresses tissue factor (TFMPs) in 80 women with breast cancer undergoing DOXO-based chemotherapy, with or without cardiotoxicity in a one-year follow-up. We observed in the cardiotoxicity group higher count of total-MPs at T0 (prior chemotherapy) (p = 0.034), CardioMPs at T0 and T1 (just after chemotherapy) (p = 0.009 and p = 0.0034) and TFMPs at T0 (p = 0.011) compared to non-cardiotoxicity group. The results suggest that MPs could be associated to cardiotoxicity due to DOXO treatment in breast cancer patients.
阿霉素（DOXO）引起的心脏毒性是乳腺癌化疗的一个限制因素。微粒（MPs）与心脏毒性之间的关系仍不清楚。MPs可在不同的病理生理条件下释放。因此，本研究旨在评估80例接受基于DOXO化疗的乳腺癌女性患者中，来源于心肌细胞的MPs（心脏MPs）、血小板的MPs（PMPs）以及表达组织因子的MPs（TFMPs），这些患者在一年的随访中有无心脏毒性。我们观察到，与无心脏毒性组相比，心脏毒性组在T0（化疗前）时总MPs计数更高（p = 0.034），在T0和T1（化疗刚结束后）时心脏MPs计数更高（p = 0.009和p = 0.0034），在T0时TFMPs计数更高（p = 0.011）。结果表明，MPs可能与乳腺癌患者DOXO治疗引起的心脏毒性有关。
Zotero 插件